REVERSE-ENGINEERING NATURE

IMPROVING HEALTH OUTCOMES IN INNOVATIVE WAYS BASED ON NATURE’S WISDOM

 

BUSINESS
MODEL

Impact Biomedical drives mission-oriented research and development that advances drug discovery and development for the prevention, inhibition, and treatment of neurological, oncology and immuno-related diseases. Other exciting technologies include breakthrough alternative sugar in the aim to combat diabetes and Functional Fragrances Formulation (3F) for industrial and medical application, amongst others. The first product in 3F’s suite of functional fragrances is 3F Mosquito which is made up of specialised oils sourced from botanicals that mosquitoes avoid. The business model of Impact Biomedical revolves mainly around two methodologies – Licensing and Sales Distribution.

Licensing

 

Impact Biomedical develop valuable and unique patented technologies which will then be licensed to big pharmaceutical companies and venture capitalists in exchange for an agreed payment (fee or royalty). This interest will rise as the validating data becomes available.

Sales Distribution

 

On the other hand, Impact Biomedical has sister companies that have in place distribution networks on a global basis. Impact Biomedical will engage in private labelling to go into production of products for sales generation. We plan to expand our geographical presence globally and intend to launch more products to add on to the flagship product range. A new retail e-commerce site will be launching in 1H2020 to allow us to take orders and deliver products.

 

FROM JUST 5 OUT OF 35 PREVIOUSLY RESTRUCTURED COMPANIES

APPROX. CURRENT MARKET CAP OVER

USD 19.9 BILLION

AND GROWING

BRINGING IN PROFITS OF OVER

USD 1 BILLION

PER ANNUM

 
 

Game Changer | Unicorn Maker | Financial Architect | ​Restructuring Expert

book2.png

ZH International Limited

Formerly Known as Heng Fai Enterprises

 

Hong Kong Stock Exchange Listed

Restructured from Bankruptcy

book1.png

Global Medical REIT

 

Hong Kong Stock Exchange Listed

Founded and Funded from Ground Zero

book4.png

Singhaiyi Ltd

Formerly Known as SingXpress Land

Singapore Exchange Listed
Restructured from Bankruptcy

book3.png

China Gas

Hong Kong Exchange Listed
Restructured from Bankruptcy

American Pacific Bank

NASDAQ Listed
Recapitalized from Bankruptcy

CHAN HENG FAI
EXECUTIVE CHAIRMAN

DIRECTORS, OFFICERS & ADVISORS

Chan Heng Fai

John 'JT' Thatch

William Harrison Lyerly, JR.

Daryl Thompson

Christina Glendening

Moe Chan

Ronald Wei

Frank D Heuszel

Scott Truesdell

Danny Lim

Michael Gershon

Jason Grady

Dr. Roscoe M. Moore

Robert Trapp

 

Products in the Pipeline

3F Antiviral Biofragrance was designed for the Open Air Defense Initiative, a strategy to protect locations where large numbers of people gather or transit such as airports, containment areas, train stations, convention centers, hospitals, and ports of entry. The concept is rather than quarantine people from the virus, quarantine the virus from people. 3F Biofragrance technology also provides protection against mosquito-borne diseases such as Zika, Malaria and Dengue fever and is 10-fold more effective than DEET. 3F Mosquito uses other receptor modalities than traditional mosquito repellents to effectively blind humans to mosquitoes. The Open Air Defense Initiative was created as a solution for Event 201, a pandemic exercise conducted in 2019 by the Johns Hopkins Center for Health Security, the World Economic Forum and the Bill and Melinda Gates Foundation. Event 201 highlighted areas where public/private partnerships are vital to respond to a severe pandemic. 3F Antiviral Biofragrance is effective against E. coli, MRSA, Influenza, Rhinovirus, Tuberculosis, and COVID-19.

3f-1.png
3f-2.png

Equivir was created as a solution for Project Bioshield, a U.S. government program to conduct and support research and development activities for countermeasures in biological emergencies. Equivir is a patented OTC medication that has broad antiviral efficacy against multiple types of Influenza, Rhinovirus, Cholera, Ebola, and COVID-19.

Linebacker was modeled to shadow the Panacea program created by the US Defense Advanced Research Projects Agency (DARPA). Panacea was a research program designed to provide novel, multi-target therapeutics for unmet physiological needs. Linebacker is a patented universal therapeutic medication with demonstrated effectiveness in neurological diseases including Parkinson’s, multiple histotypes of cancer, and multiple pathogens such as MRSA, E. coli, Cholera, A. baumannii, Influenza, SARS, MERS, Malaria, and COVID-19.

A breakthrough reduced-calorie, low glycemic index, natural, modified sugar Laetose – which has the potential to affect the world’s sugar market. Laetose is a functional sugar with 30% to 50% reduced sugar. This patent-pending breakthrough invention gives the world access to an alternative to sugar with a nearly 50% lower glycemic index (“GI”) which also assists in mitigating inflammatory responses by improving the process of glucose absorption throughout the body.

FAQ on Laetose:

Is the Laetose a byproduct of sugar? What is it derived from?

Laetose is sugar how nature designed it. Laetose contains key compounds found in fruits and vegetables that make sugar healthier for the human body. Laetose is sugar that contains key ingredients from fruits and vegetables.

Sugar is also used for functional purposes, how does Laetose perform there

Laetose sugar is low glycemic and is 100% as sweet as sugar but contains 30% less sugar. Laetose was specifically designed to address the global need to fight Diabetes and Obesity by reducing sugar consumption.

 

What makes this new sugar healthier?

Laetose contains key insulino mimetic compounds that are found in fruits and vegetables.

 

How can you classify it as “naturally modified?” What is the process exactly?

Laetose is sugar that is recombined with natural anti-glycemic compounds found naturally if fruits and vegetables to make sugar a much safer product. Everything in nature that is high in sugar that is good for us contains anti-glycemic compounds. These can be grapes, oranges, cranberries, blue berries, etc. They are high in sugar but contain unique compounds that make sugar harmless by reducing inflammation caused by high sugar consumption. We isolate these compounds and simply add them back to purified sugar. The process is very similar to how candy is manufactured.

 

What is the next step? Do you plan to take it to market and how?

Yes, Laetose is being presently being reviewed by most of the largest sugar manufacturers in the world.

Quantum, a new frontier in pharmaceutical development. Quantum is a new class of medicinal chemistry that uses advanced methods to boost efficacy and persistence of natural compounds and existing drugs while maintaining the safety profile of the original molecules. Instead of modifying functional groups, as is typically done presently in drug discovery, this new technique alters the behavior of molecules at the sub-molecular level.

This approach can be used to enhance and patent natural compounds which includes many substances used in traditional medicines around the world.

Plastics are an incredibly useful tool in the modern age but they do come with several negative disadvantages. Currently the oceans are being inundated annually with 8 million metric tons of plastics. A rate in which our planet cannot endure. Impact Biomedical is currently developing technologies to re-invent plastics as an effective tool as well as make them not only bio-friendly but more importantly bio-compatible.

 

We are researching and exploiting key strategies found in the biological realm that can create plastics that are highly beneficial. The lessons learned from nature and how it organizes plastic like materials can help us design advanced  plastics that break down into bio-digestible fragments that will mitigate the impact of bio-accumulation of plastics in our oceans. Another key aspect is the creation of radiometric manipulation technology used by chlorophyll in plants that can lead us to developing UVA and UVB protective fibers for clothing. A material  of this type may be an invaluable defense against skin cancer. We are also developing research into antimicrobial fibers that can be used in surgical instruments, wound dressings and common band aids that actively fight infection such as Ecoli, MRSA and Staph and accelerate healing. And finally we are advancing rapidly into plastics that can be utilized in common products such as cups, plates, plastic bags and counter tops with unique antimicrobial properties that act to control the spread of active pathogens such as SARS-Cov2, Influenza and Rhinovirus from person to person contact

Our science team is currently engaged in the research and development of nanoparticle platforms for biodefense applications. The use of novel nanoparticle technology represents an emerging and exciting field in biomedical discovery directed at the prevention and mitigation of life threatening pandemics. Our nanoparticle research is focused on significantly improving the effectiveness of present day therapeutics via inorganic nano scale modifications. 

Medical Foods are foods that are specially formulated and intended for the dietary management of a disease that has distinctive nutritional needs that cannot be met by normal diet alone. Impact Biomedical is actively developing therapeutic medical foods for the treatment and management of Neurological Disorders, Diabetes, Metabolic Syndrome, Bacterial and Viral Infection.

 
 
 
 
 
 
 
 
 

FUTURE PROJECTS

Unveiling Soon

 
 

MEDIA

 
Videos
Press Release
Title
Date

Impact BioMedical to Begin Efficacy Testing of Pan-Coronavirus Vaccine Under New Wholly Owned
Subsidiary - Innate Immune, Inc.

Impact BioMedical Demonstrates 10-Fold Reduction in Viral Population of COVID-19 in Surface Disinfectant Efficacy Testing of its 3F Antiviral Biofragrance

Impact BioMedical Initiates Bioplastics Research Collaboration with One of World’s Largest Plastic Manufacturers

COMPLETION OF THE US$50 MILLION SHARE SWAP

DOCUMENT SECURITY SYSTEMS, INC.’S SHAREHOLDERS APPROVE PROPOSED US$50.0 MILLION SHARE SWAP

Impact Biomedical initiates Quantum Research Program to solve the Patent Cliff

IMPACT BIOMEDICAL ACHIEVES COVID-19 SUCCESS WITH EQUIVIR AND 3F BIOFRAGRANCE RESPONSES TO QUERIES RAISED BY THE SGX-ST

Impact Biomedical Achieves COVID-19 Success with Equivir and 3F Biofragrance

Impact Biomedical Announces Publication of COVID-19 Research in Peer-Reviewed Journal

Singapore eDevelopment Limited's Notice of Extraordinary General Meeting to be held on 26 June 2020 in relation to the Proposed US$50 million Share Swap

 
 

CONTACT
US

OUR ADDRESS

United States

Hampden Square 4800 Montgomery Lane, Suite 210

(1) 301 971 3955T /  (1) 301 971 3940

Singapore

7 Temasek Boulevard #29-01B Suntec Tower One Singapore 038987

(65) 6333 9181

Hong Kong

7/Floor, Skyway Centre, 23 Queen’s Road West Sheung Wan, Hong Kong

(852) 2711 1808

Back to Top

BACK TO TOP

© 2020 impbio.com. All Rights Reserved.